NSE · BSE · Real-time

Breaking Corporate Events, Analysed in Real Time

High-value corporate events — new orders, fund raises, capacity expansions, and earning calls — analysed by AI the moment they hit the exchange.

All New Order Fund Raise Expansion Earning Call Regulatory Approval Production Started Product Launched
Tagged Oncology
Zydus Lifesciences and Apollo Hospitals Partner to Launch Shield Multi-Cancer Detection Test
Product Launched

Zydus Lifesciences and Apollo Hospitals Partner to Launch Shield Multi-Cancer Detection Test

Zydus Lifesciences has entered into a Memorandum of Understanding with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection (MCD) test in India. This partnership utilizes Zydus's exclusive agreement with Guardant Health to provide a non-invasive, blood-based screening tool for 10 common cancer types.

Zydus Lifesciences Ltd (532321)
3 Jul 2026 4 min read
Shilpa Medicare Commissions Integrated ADC Manufacturing Facility in Dharwad
Production Started

Shilpa Medicare Commissions Integrated ADC Manufacturing Facility in Dharwad

Shilpa Biologicals Private Ltd, a subsidiary of Shilpa Medicare, has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP manufacturing facility. Located in Dharwad, the plant enables end-to-end production of complex oncology biologics for global markets.

Shilpa Medicare Ltd
24 Jun 2026 4 min read
Shilpa Medicare Subsidiary Commissions Integrated ADC GMP Facility in Dharwad
Expansion

Shilpa Medicare Subsidiary Commissions Integrated ADC GMP Facility in Dharwad

Shilpa Biologicals Private Ltd, a subsidiary of Shilpa Medicare, has commissioned an integrated Antibody-Drug Conjugate (ADC) GMP manufacturing facility in Dharwad. This advanced unit enables the company to offer end-to-end development and production of complex oncology drug substances for the global pharmaceutical market.

Shilpa Medicare Ltd (530549)
24 Jun 2026 4 min read
Dr. Reddy's Launches First Generic Bosulif in US Market for $253.8M Opportunity
Product Launched

Dr. Reddy's Launches First Generic Bosulif in US Market for $253.8M Opportunity

Dr. Reddy's Laboratories has launched the first-to-market generic version of Bosulif (Bosutinib Tablets 400mg) in the United States. This strategic oncology launch, executed in collaboration with MSN Laboratories, grants the company 180 days of generic drug exclusivity for this specific dosage strength.

Dr Reddys Laboratories Ltd (500124)
13 Jun 2026 4 min read